CCRA Investigational Product Management 1 — Questions and Answers
Question 1: What is the purpose of investigational product (IP) accountability at a clinical trial site?
- To calculate the sponsor's manufacturing costs
- To ensure accurate records of all IP received, dispensed, returned, and destroyed to verify subject compliance and prevent misuse (Correct answer)
- To track IP shipment transit times
- To monitor competitive product use by subjects
Correct answer: To ensure accurate records of all IP received, dispensed, returned, and destroyed to verify subject compliance and prevent misuse
IP accountability requires maintaining records showing the disposition of every unit of investigational product to confirm it was used only for trial purposes and that subjects received the correct doses.
Question 2: A 'temperature excursion' for investigational product occurs when:
- The IP is shipped to an unapproved country
- IP storage conditions deviate outside the protocol-specified temperature range (Correct answer)
- The IP dispensing log shows missing entries
- The IP expiration date passes without disposal
Correct answer: IP storage conditions deviate outside the protocol-specified temperature range
A temperature excursion is when IP is exposed to temperatures outside the specified storage range; the sponsor's medical/quality team must evaluate whether the affected IP remains usable.
Question 3: Who is authorized to dispense investigational product at a clinical trial site?
- Any site staff member listed on the trial team list
- Only qualified personnel delegated and documented on the Delegation of Authority Log, typically the pharmacist or designated nurse/coordinator (Correct answer)
- The CRA during monitoring visits
- Any licensed pharmacist regardless of trial training
Correct answer: Only qualified personnel delegated and documented on the Delegation of Authority Log, typically the pharmacist or designated nurse/coordinator
Only personnel specifically trained and authorized on the site's Delegation of Authority Log may dispense IP; this typically requires trial-specific training and pharmacy or nursing qualifications.
Question 4: During IP reconciliation at a monitoring visit, the CRA discovers more units were dispensed than accounted for in subject dosing records. The FIRST action is to:
- Destroy the excess IP immediately
- Investigate the discrepancy with site staff and document findings; notify the sponsor if unresolved (Correct answer)
- Assume it is a counting error and move on
- Report the site to the FDA immediately
Correct answer: Investigate the discrepancy with site staff and document findings; notify the sponsor if unresolved
IP discrepancies must be investigated with site staff to identify the cause; if unexplained, the sponsor must be notified, and depending on severity, regulatory reporting or a for-cause audit may be required.
Question 5: The 'randomization code' in a blinded clinical trial is maintained to:
- Allow site coordinators to optimize treatment allocation
- Enable emergency unblinding for subject safety and final unblinding for statistical analysis (Correct answer)
- Reduce the number of placebo-assigned subjects
- Ensure balanced age distribution across treatment arms
Correct answer: Enable emergency unblinding for subject safety and final unblinding for statistical analysis
Randomization codes are securely maintained so they can be accessed in emergencies (e.g., to determine treatment for safety management) and at study end for statistical analysis.
Question 6: When investigational product is returned from a site for destruction, the CRA must confirm:
- The site has purchased replacement supplies
- All returned IP is properly labeled, logged, and accompanied by documentation confirming quantities and condition (Correct answer)
- The returned IP is tested for potency before destruction
- The subjects who used the IP have signed an additional consent
Correct answer: All returned IP is properly labeled, logged, and accompanied by documentation confirming quantities and condition
Returned IP must be documented with quantities matching records, properly labeled, and accompanied by return authorization documentation; this ensures full accountability and proper destruction.
CCRA Investigational Product Management 1
What is the purpose of investigational product (IP) accountability at a clinical trial site?